Daewon Pharmaceutical will present data on DW5324, an oral semaglutide candidate showing up to 3.14 times the drug exposure ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results